DUBLIN, Oct. 9, 2024 (Globe Newswire) — The “Non-infectious Macular Edema Treatment – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.
The global non-infectious macular edema treatment market was estimated at USD 17.1 billion in 2023 and is projected to reach USD 25 billion by 2030, growing at a CAGR of 5.6% from 2023 to 2030 . This comprehensive report provides detailed analysis. Understand market trends, drivers, and forecasts to help you make informed business decisions.
Early and effective treatment is critical to maintaining quality of life, especially for patients with chronic diseases such as diabetes. The treatment landscape has significantly advanced with the introduction of anti-VEGF therapy. Anti-VEGF therapy specifically targets abnormal blood vessels that contribute to fluid leakage and macular swelling, providing patients with better outcomes and fewer side effects than traditional treatments.
What are the key growth drivers of the non-infectious macular edema treatment market?
The growth of the non-infectious macular edema treatment market is driven by several key factors, including the rising prevalence of diabetes and associated retinal complications such as diabetic macular edema. As more people around the world are being diagnosed with diabetes, there is a growing need for effective treatments for macular edema. Another important driver is the widespread use of anti-VEGF therapies. Anti-VEGF therapy significantly improved outcomes in patients with macular edema by reducing fluid accumulation and improving visual acuity.
Technological advances in drug delivery systems, such as sustained-release implants, are also driving market growth by providing longer-term treatment and reducing the burden of frequent injections. Additionally, as the population ages, age-related eye conditions become more common, increasing the demand for macular edema treatment. Increasing focus on early diagnosis and treatment, supported by advanced imaging technologies such as optical coherence tomography (OCT), is enabling more accurate and effective treatment strategies, further driving market expansion. Masu.
How is the non-infectious macular edema treatment market evolving?
The non-infectious macular edema treatment market is evolving with the increasing availability of targeted biological therapies such as anti-VEGF injections, which have become the standard of care for many patients. One important trend is the increasing use of biologics such as ranibizumab and aflibercept, which are designed to inhibit abnormal blood vessel growth and reduce fluid leakage within the retina. These treatments have proven to be highly effective in improving vision and reducing the need for more invasive treatments such as laser therapy and surgery.
Another important trend is the development of long-acting corticosteroid implants and sustained-release drug delivery systems. These innovations reduce the frequency of treatments, increase patient convenience, and improve adherence to treatment plans. Additionally, advances in imaging technologies such as optical coherence tomography (OCT) have improved the diagnosis and monitoring of macular edema, allowing for more precise and personalized treatment approaches. As researchers continue to explore new treatments targeting inflammation and fluid accumulation, the market is expected to expand and provide more options for patients.
Which patient groups are driving the demand for macular edema treatment?
Demand for non-infectious macular edema treatments is primarily driven by patients with chronic conditions that increase the risk of macular edema, especially those with diabetic retinopathy. As diabetes becomes more prevalent worldwide, the incidence of diabetic macular edema is increasing, increasing the demand for effective treatments. Similarly, patients with retinal vein occlusion (RVO), a condition that can cause fluid buildup within the retina, are important users of macular edema treatments.
Another major group of patients includes people with uveitis, an inflammatory disease of the eye that can cause macular edema. These patients often require corticosteroids or immunosuppressive therapy to manage inflammation and prevent vision loss. The aging of the population is also a key driver of demand, as older people are more likely to experience macular edema due to age-related retinal conditions. Early diagnosis and timely treatment are critical for these patients to preserve their vision and maintain their independence.
Key insights:
Market Growth: Understand the significant growth trajectory of the anti-VEGF drugs segment, expected to reach USD 16.6 billion by 2030 at a CAGR of 5.3%. The corticosteroid drugs segment is also expected to grow at a CAGR of 6.7% during the analysis period. Regional Analysis: Gain insight into the US market, valued at $4.6 billion in 2023, and the China market, expected to grow at an impressive CAGR of 5.2% by 2023. Check out growth trends in other key regions such as Japan, Canada, Germany, and Asia Pacific.
Report features:
Comprehensive market data: Independent analysis of annual sales and market forecasts (USD million) from 2023 to 2030. Detailed regional analysis: Detailed insights into key markets including the US, China, Japan, Canada, Europe, Asia Pacific, and Latin. America, Middle East, Africa. Company Profile: Covers major companies such as AbbVie, Inc., Alimera Sciences, Inc., and Allergan PLC. Free updates: Receive 1 year of free report updates to stay informed. Latest market trends.
Key attributes:
Report attribute details No. Number of pages 196 Forecast period 2023 – 2030 Estimated market value in 2023 (USD) 17.1 billion USD Predicted market value by 2030 (USD) 25 billion USD Average annual growth rate 5.6% Target region Worldwide
Main topics covered:
Market overview
Influencer Market Insights Global Market Trajectory Global Economic Updates Non-infectious Macular Edema Treatment – Market Share Percentages of Major Global Competitors in 2024 (E) Competitive Market Presence – in 2024 Powerful/Active/Niche/Mediocre (E) for players around the world
Market trends and drivers
Rising prevalence of non-infectious macular edema (NIME) drives demand for advanced treatment solutions Increased adoption of anti-VEGF therapies expands market for effective non-infectious macular edema treatment Corticosteroids Increased use of implants strengthens market for long-term management of non-infectious macular edema Advances in technological ophthalmic drug delivery drive growth in sustained-release treatment options in NIME Increasing focus on minimally invasive treatments drives NIME Expanding opportunities for intraocular injections and implants in NIME Increased adoption of combination therapy in NIME expands market for combined treatment approaches Increased focus on retinal imaging and diagnostic tools Growth in early detection and monitoring of non-infectious macular edema Increased use of personalized medicine and genetic testing expands opportunities for targeted NIME treatments Increased use of anti-inflammatory agents in non-infectious macular edema expands the market for corticosteroid and immunosuppressant treatments Increased focus on expanding drug resistance Non-infectious macular edema expands market for innovative treatment solutions Nanotechnology developments drive growth in non-infectious macular edema drug delivery systems Biologics in non-infectious macular edema treatment Rising demand for drugs strengthens market for advanced therapeutics
Focus on carefully selected players (46 players in total)
AbbVie, Inc.Alimera Sciences, Inc.Allergan PLCAmgen, Inc.Bausch Health Companies, Inc.Bayer AGClearside Biomedical, Inc.F.Hoffman La Roche AGNovartis International AGPfizer, Inc.
For more information on this report, please visit https://www.researchandmarkets.com/r/n2t5hi.
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source of international market research reports and market data. We provide the latest data on international and regional markets, key industries, top companies, new products and latest trends.
Non-infectious macular edema treatment market
